Results 141 to 150 of about 3,046 (215)

Mavacamten and left ventricular dysfunction in hypertrophic cardiomyopathy with left bundle branch block

International audienceBackground: Mavacamten is a cardiac myosin inhibitor used for patients with obstructive hypertrophic cardiomyopathy (oHCM). The efficacy and safety of this negative inotropic agent in oHCM and concomitant left bundle branch block ...
Donal, Erwan, de Pooter, Jan, Gonzalez de Alaiza Ortega, Sara, van Overmeiren, Thomas, Timmermans, Frank, Calle, Simon, de Alaiza Ortega, Sara Gonzalez   +6 more
core   +1 more source

Establishment and Validation of a Stability-Indicating RP-HPLC Protocol for Mavacamten in Oral Capsule Preparations. [PDF]

Turk J Pharm Sci
Daroi PA, Patil P, Munipalli V, Sonawane B.   +3 more
europepmc   +1 more source

Myosin inhibitor therapy in Fabry cardiomyopathy with dynamic left ventricular outflow obstruction. [PDF]

Am Heart J Plus
Lau K, Petri N, Nordbeck P.
europepmc   +1 more source

Prospective evaluation of real-world safety, symptoms improvement and adherence to mavacamten among Iranian patients with hypertrophic obstructive cardiomyopathy (PERSIA-HOCM): protocol of a multicentre observational study. [PDF]

BMJ Open
Ghaseminejad-Raeini A, Karimi MA, Shirinezhad A, Aslani M, Soheili A, Ghaderi A, Haghjoo M, Bakhshandeh H, Naderi N.   +8 more
europepmc   +1 more source

Post-marketing safety signal profile of mavacamten in the FDA adverse event reporting system (FAERS): a disproportionality analysis. [PDF]

Front Pharmacol
Wu J, Chen C, Zheng T.
europepmc   +1 more source

Response to: "Comparative hemodynamic effects of mavacamten and septal myectomy in HOCM: important methodological considerations". [PDF]

Cardiovasc Diagn Ther
Chen Y, Luo X, Yang Y, Ou J, Liu H.
europepmc   +1 more source

The Central Role of Echocardiography in Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy: A Comprehensive Review. [PDF]

Cardiol Res Pract
Nizam A, Antoun I, Hodson L, Ng GA, Dhutia H.   +4 more
europepmc   +1 more source

Borderline Significance or Biological Signal? Reinterpreting the ODYSSEY-HCM Trial in Non-obstructive Hypertrophic Cardiomyopathy. [PDF]

Eur Cardiol
Prajapathi S, Mohta A, Shah B, Pradhan A.   +3 more
europepmc   +1 more source

Comparative hemodynamic effects of mavacamten and septal myectomy in HOCM: important methodological considerations. [PDF]

Cardiovasc Diagn Ther
Imamura T.
europepmc   +1 more source

Correction to: Mavacamten: First Approval

Drugs, 2022
openaire   +1 more source